What is System1 Biosciences?
System1 Biosciences, Inc. is a San Francisco-based neurotherapeutics company dedicated to discovering novel drugs for complex neurological and psychiatric diseases. Leveraging a sophisticated approach that combines cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics, the company aims to address disorders such as epilepsy, autism, and schizophrenia, where traditional discovery methods have faced limitations. By generating deep phenotypes of disease, System1 seeks to identify previously unrecognized therapeutic targets and develop innovative drug treatments.
How much funding has System1 Biosciences raised?
System1 Biosciences has raised a total of $25.3M across 2 funding rounds:
Series A
$25M
Debt
$350K
Series A (2018): $25M with participation from Riot Ventures, Alexandria Venture Investments, Pfizer Venture Investments, CRV, Boom Capital, Wilmot Ventures, Dolby Family Ventures, Liquid2 Ventures, Kinled Holding, Longevity Fund companies, and Webb Investment Funding
Debt (2020): $350K led by PPP
Key Investors in System1 Biosciences
Riot Ventures
Riot Ventures focuses on modernizing critical industries through investment in iconic companies, with funding amounts reaching up to $100 million. Their portfolio includes a diverse range of innovative firms, such as satellite builders, AI technology providers, and advanced robotics companies.
Alexandria Venture Investments
Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry, offering its properties for lease primarily to universities and pharmaceutical, biotechnology, and life science entities.
Pfizer Venture Investments
Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas, focusing on oncology, internal medicine, inflammation and immunology, and vaccines.
What's next for System1 Biosciences?
The substantial enterprise-level funding indicates a critical growth phase for System1 Biosciences. This capital infusion is expected to accelerate the company's drug discovery pipeline, expand its research and development capabilities, and potentially facilitate clinical trials. The strategic nature of the recent investment suggests strong alignment with key industry players, positioning System1 to advance its mission of tackling challenging neurological conditions.
See full System1 Biosciences company page
